Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO
Not Applicable
Completed
- Conditions
- Leptospirosis
- Interventions
- Other: two additional blood samples specific to research
- Registration Number
- NCT05413720
- Lead Sponsor
- Centre Hospitalier Universitaire de la Réunion
- Brief Summary
The research hypothesis is based on a suspected strong involvement of the immune system in the genesis of serious manifestations of the disease (hepatitis, renal failure, thrombocytopenia, intra-alveolar hemorrhage). The question asked is that of the state of the immune system (quantitative and qualitative: activation markers, production of cytokines) evaluated by the study of circulating innate immune cells (monocytes, neutrophils, dendritic cells, lymphocytes, platelets).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Age ≥ 4 years;
- Weight ≥ 11 kg;
- with ongoing symptoms compatible with a clinical diagnosis of leptospirosis.
- AND having a diagnosis of leptospirosis confirmed according to standard care procedures: preferably by Polymerase Chain Reaction (PCR) (blood or urine) or, failing that, serology indicating a recent infection (positive Immunoglobulin M (IgM) or Microscopic Agglutination Test (MAT) technique with titer >1/400 for a pathogenic serogroup)
- AND affiliated to a Social Security scheme
Exclusion Criteria
- Refusal of participation by the patient or his entourage if the patient is physically unable to give his opinion (coma, resuscitation, etc.).
- Not affiliated with social security
- Immunosuppression that may interfere with the interpretation of the results: chemotherapy in progress, immunosuppressants in progress for organ transplantation or autoimmune disease
- Patient under legal protection (Guardianship, Curators)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Patient with leptospirosis two additional blood samples specific to research -
- Primary Outcome Measures
Name Time Method proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes at inclusion
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
CHU de la Réunion
🇷🇪Saint-Pierre, Réunion
CHOR
🇷🇪Saint-Paul, Réunion
GHER
🇷🇪Saint-Benoît, Réunion